Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Wilhelm, Martin ^a   Smetak, Manfred ^a   Schaefer Eckart, Kerstin ^a   Kimmel, Brigitte ^b   Birkmann, Josef ^a   Einsele, Hermann ^b   Kunzmann, Volker ^b  

^a KLINIKUM NÜRNBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adoptive transfer; Bisphosphonate; Haploidentical T lymphocytes; in vivo cell expansion; Innate immunity; Interleukin 2; NK cells

Indexed keywords

ADOPTIVE TRANSFER; ADULT; AGED; CELL PROLIFERATION; HUMANS; MALE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84894250758     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-45     Document Type: Article

References (20)

1. Ruggeri L, Capanni M, Urbani S, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100. 10.1126/science.1068440, 11896281.
2. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105(8):3051-3057. 10.1182/blood-2004-07-2974, 15632206.
3. Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol 2001, 114:11-24. 10.1046/j.1365-2141.2001.02906.x, 11472339.
4. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukaemia. J Clin Oncol 2010, 28:955-959. 10.1200/JCO.2009.24.4590, 2834435, 20085940.
5. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukaemia patients. Blood 2011, 118:3273-3279. 10.1182/blood-2011-01-329508, 21791425.
6. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
7. Kunzmann V, Wilhelm M. Anti-Lymphoma effect of γδ T cells. Leukemia Lymphoma 2005, 46:671-680. 10.1080/10428190500051893, 16019504.
8. Kunzmann V, Bauer E, Wilhelm M. γδ T cell stimulation by pamidronate. N Engl J Med 1999, 340:737-738. 10.1056/NEJM199903043400914, 10068336.
9. Wang H, Henry O, Distefano MD, Wang YC, Räikkönen J, Mönkkönen J, Tanaka Y, Morita CT. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013, 191(3):1029-1042. 10.4049/jimmunol.1300658, 23833237.
10. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. γδ T cells for Immune therapy of patients with lymphoid malignancies. Blood 2003, 102:200-206. 10.1182/blood-2002-12-3665, 12623838.
11. Kunzmann V, Smetak M, Kimmel B, Weissinger F, Weigang-Koehler K, Birkmann J, Einsele H, Wilhelm M. γδ T cell-mediated immunotherapy of malignancies with zoledronate and IL-2 [abstract]. Blood 2005, 106(11):s2439.
12. Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M. Inhibition of phosphoantigen-mediated γδ T cell proliferation by CD4+CD25+FoxP3+ regulatory T cells (Treg). Immunology 2009, 126(2):256-267. 10.1111/j.1365-2567.2008.02894.x, 2632687, 18775028.
13. Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M, Kunzmann V. Clinical-scale single-step CD4+ and CD8+ cell depletion for Donor Innate Lymphocyte Infusion (DILI). Bone Marrow Transplant 2008, 41:643-650. 10.1038/sj.bmt.1705942, 18037935.
14. Young KJ, Kay LS, Phillips MJ, Zhang L. Antitumor activity mediated by double negative T cells. Cancer Res 2003, 63:8014-8021.
15. Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001, 182:190-200. 10.1034/j.1600-065X.2001.1820115.x, 11722634.
16. Napolitano A, Pittoni P, Beaudoin L, Lehuen A, Voehringer D, MacDonald HR, Dellabona P, Casorati G. Functional education of invariant NKT cells by dendritic cell tuning of SHP-1. J Immunol 2013, 190:3299-3308. 10.4049/jimmunol.1203466, 23427253.
17. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H. Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol 2012, 95:624-631. 10.1007/s12185-012-1091-0, 22592322.
18. Motohashi S, Nakayama T. Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy 2009, 1:73-82. 10.2217/1750743X.1.1.73, 20635975.
19. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, Von Blomberg BM, Bontkes HJ. Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 2008, 129:182-194. 10.1016/j.clim.2008.07.025, 18783990.
20. Haraguchi K, Takahashi T, Nakahara F, Matsumoto A, Kurokawa M, Ogawa S, Oda H, Hirai H, Chiba S. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma 2006, 47:2218-2223. 10.1080/10428190600682688, 17071498.